An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy
Estelle Lach‐Trifilieff, Giulia Minetti, Kelly-Ann Sheppard et al. · Molecular and Cellular Biology · 2013
The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size. Several other ligands, including GDF11 and the activins, signal through this pathway, suggesting that the ActRII receptors are major regulatory nodes in the regulation of muscle mass. We have developed a novel, human anti-ActRII antibody (bimagrumab, or BYM338) to prevent binding of ligands to the receptors and thus inhibit downstream signaling. BYM338 enhances differentiation of primary human skeletal myoblasts and counteracts the inhibition of differentiation induced by myostatin or activin A. BYM338 prevents myostatin- or activin A-induced atrophy through inhibition of Smad2/3 phosphorylation, thus sparing the myosin heavy chain from degradation. BYM338 dramatically increases skeletal muscle mass in mice, beyond sole inhibition of myostatin, detected by comparing the antibody with a myostatin inhibitor. A mouse version of the antibody induces enhanced muscle hypertrophy in myostatin mutant mice, further confirming a beneficial effect on muscle growth beyond myostatin inhibition alone through blockade of ActRII ligands. BYM338 protects muscles from glucocorticoid-induced atrophy and weakness via prevention of muscle and tetanic force losses. These data highlight the compelling therapeutic potential of BYM338 for the treatment of skeletal muscle atrophy and weakness in multiple settings.
Cited by 306 works. doi:10.1128/mcb.01307-13
Authors
- Estelle Lach‐Trifilieff
- Giulia Minetti
- Kelly-Ann Sheppard
- Chikwendu Ibebunjo
- Jérôme N. Feige
- Steffen F. Hartmann
- Sophie Brachat
- Helene Rivet
- Claudia Koelbing
- Frédéric Morvan
- Shinji Hatakeyama
- David J. Glass
References
- Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
- Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo
- Double muscling in cattle due to mutations in the myostatin gene
- Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways
- Regulation of myostatin activity and muscle growth
- Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
- A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep
- Induction of Cachexia in Mice by Systemically Administered Myostatin
- Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
- A Mutation in the Myostatin Gene Increases Muscle Mass and Enhances Racing Performance in Heterozygote Dogs